Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

M. Ernest Marshall, Michael K. Wolf, E. David Crawford, Sarah Taylor, Brent Blumenstein, Robert Flanigan, Frederick J Meyers, Harry E. Hynes, Bart Barlogie, Mario Eisenberger

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)207-209
Number of pages3
JournalInvestigational New Drugs
Volume11
Issue number2-3
DOIs
StatePublished - Jun 1993

Keywords

  • echinomycin
  • kidney
  • renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Marshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., Meyers, F. J., Hynes, H. E., Barlogie, B., & Eisenberger, M. (1993). Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study. Investigational New Drugs, 11(2-3), 207-209. https://doi.org/10.1007/BF00874157